Costello syndrome is an extremely rare genetic disorder with growth delay after birth and typically results in short stature during childhood. It is one of the RASopathy of Ras/MAPK pathway syndromes. It affects the transforming protein p 21 , an enzyme that in humans is encoded by the HRAS gene. H-Ras is a small G protein and once bound to Guanosine triphosphate, it will activate a Raf kinase like C-Raf, the next step in the MAPK/ERK pathway (mitogen-actvated protein kinase/ extracellular signal-regulated kinase) i.e., MEK (mitogen-actvated ERK kinase), a protein that phosphorylate ERK which can directly and indirectly activate many transcription factors. This pathway is also known as Ras-Raf, MEK-ERK pathway, which is a chain of proteins on the cell that communicate a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell. Activation of ERK 1/2 is involved in signal transduction pathways associated with cardiac hypertrophy. The developmental syndromes caused by germline mutations in genes that alter the RAS components of the MAP/ERK signal transduction pathway are called "RASopathies". Cardiovascular abnormalities are important features of Costello syndrome and other RASopathies such as Noonan syndrome. Background of this case report described the congenital valvular pulmonic stenosis and ventriculomegaly associated with Costello syndrome by transthoracic echocardiographic imaging in a 9-year-old male boy.
joints, loose folds of extra skin and structural malformations of the heart present at birth such as valvular pulmonic stenosis and abnormal thickening of the muscular walls of the ventricles (ventriculomegaly). It was discovered by Dr. Jack Costello, a New Zealand paediatrician in 1977 [1] . Costello syndrome is inherited as an autosomal dominant genetic condition due to mutations in the HRAS gene which results in production of H-Ras protein that leads to continuous cell growth and division, causing ventriculomegaly. HRAS is a proto-oncogene and the affected individuals have an approximately 15% lifetime risk to develop tumors such as papillomas, rhabdomyosarcoma, neuroblastoma, transitional cell carcinoma of bladder and hurthle cell carcinoma of thyroid (a follicular carcinoma, oxyphil type). These genetic mutations in HRAS causing Costello syndrome were first reported in 2005 [2] and 200 to 350 cases were reported worldwide.
Isolated pulmonic valve stenosis with dome-shaped pulmonic valve was described in 1761 by John Baptist Morgagni [3] . It occurs with an incidence of 1.5 -6.5 per 10,000 live births, accounting for 2% to 13% of all congenital heart lesions [4] . In patients with isolated congenital pulmonic valve stenosis (no other valves or congenital cardiac condition), congenital malformations of the valve are two types; dome-shaped acommissural and dysplastic. Acommissuralstenotic pulmonic valve is usually a dome-shaped structure with a central aperture and ridges are visible that mark sites of apparently malformed commissures [5] . In dysplastic pulmonic stenosis, the pulmonic valve is a tricuspid structure and all three cusps are greatly thickened, rubbery and composed of disorganized myxomatous tissue and no commissural fusion but the valve annulus is small and pulmonary trunk is not dilated. Gikonyo and colleagues [6] found that all congenital forms had thickened cusps with or without commissural fusion. Altrichter [7] reported that 58% of stenotic pulmonic valves were bicuspid in 65 patients with Tetralogy of Fallot. The quadricuspid state of the pulmonic valve is seen in 1 in 10,000 cases at necropsy series and the frequency of dysfunctional quadricuspid pulmonic valves range from 4% to 6% [8] .
The incidence of isolated congenital pulmonic valve stenosis is uncommon in Costello syndrome and so this case has been reported.
Case Report
A 9-year-old male boy was referred from the school with a history of growth retardation from childhood for evaluation. He was asymptomatic and no history of cyanosis at birth. His school performance in studies was not affected compared to other students. His pulse rate was 80 bpm and blood pressure 110/80 mmHg. General examination revealed short stature, low-set ears, prominent head, skin folding below the lower eyelids, teeth abnormalities and skeletal changes such as mild ulnar deviation of elbows and hands, kyphoscoliosis, shortening of arms and thighs, tight tendoachilles and plantar hyperkeratosis , which are consistent with features of Costello syndrome as shown in Figures 1-4 . Physical examination revealed grade 3/6 systolic murmur over the precordium, most prominent in left 2 nd intercostal space. The second heart sound was inaudible. No phasic ejection clicks due to merging of it with 1 st heart sound in severe stenosis, Jugular venous pulsation was not present and no parasternal heave. Blood chemistry revealed normal (Haemoglobin-13.7 gm% (normal-12 to 16 g/dl), total count-9000 cells (normal-4 to 11,000 cells) per cubic mm of blood, Differential count-polymorphs-60% (normal-40% to 70%), lymphocytes-30% (normal-20% to 40%), eosinophils-4% (normal-1% to 4%), Erythrocyte sedimentation rate-2 to 4 mm/hour (normal-0 to 9 mm/hour) and platelets-2.56 lakhs (normal-2.5 to 5 lakhs) per cubic mm of blood, ASO (anti-sreptolysin O) titer was negative (<200 IU/ml). ECG revealed right ventricular strain pattern as shown in Figure 5 . The maximum height of R wave in V 1 is 14 mm (5 mm standardization in ECG) which corresponds to right ventricular systolic pressure of 70 mmHg (14 × 5 = 70 mmHg) and deep S in V 6 . X-ray chest revealed prominent main pulmonary artery segment resulting from poststenotic dilatation of the pulmonary trunk and right ventricular hypertrophy as shown in Figure 6 .
Transthoracic Echocardiographic images in Figures 7-21 given below revealed thickened, calcified, pulmonary valve with commissural fusion, severe pulmonary valve stenosis with poststenotic dilatation, suprasystemic ventricular systolic pressures and ventriculomegaly.
These features are consistent with isolated congenital valvular pulmonic stenosis and ventriculomegaly in Costello syndrome and the child was advised periodic follow-up. Screening of family members revealed normal.
Discussion

Etiopathogenesis
Costello syndrome is caused by any of at least 5 -different heterogenous germline mutations in the proto-onco- gene HRAS on chromosome 11, involved in controlling cell growth and division on multiple organ system These mutations produce H-Ras protein which is permanently active and this overactive protein direct cells to grow and divide constantly leading to overgrowth of heart muscle (hypertrophic cardiomyopathy) as shown in Figure 8 . Infants with Costello syndrome may be large at birth, but grow more slowly than the other children. Later in life, this condition has relatively short stature as shown in Figure 2 and many have reduced levels of growth hormone and it is a "RASopathy", also called as "Faciocutaneoskeletal syndrome" (FCS syndrome). In some cases, the symptoms and findings of Costello syndrome overlap with two similar disorders known as Noonan syndrome, Cardio faciocutaneous syndrome which are caused by mutations in different genes and characterized by webbing of neck, drooping of upper eyelids (ptosis) and mostly associated with dysplastic pulmonic valve.
The exact embryologic process resulting in pulmonic valve stenosis is not well understood. Maldevelopment of the distal part of the bulbous cordis has been proposed [9] , but it appears unlikely that fusion of well-formed pulmonic valve cusps would occur during mid-to late intrauterine development after the ventricular septum has been completed [10] . Fused cusps of varying thickness and rigidity form a fibrous dome in the severest form and contribute the most common form of isolated valvular pulmonic stenosis. Fetal endocarditis has been proposed as a cause but not proven [11] . Maternal rubella infection may be associated with stenosis of the pulmonary artery and its branches. Genetic factors also play a role. In the classic form of pulmonic valve stenosis, the valve is conical or dome-shaped and 2 -4 raphes may be visible, but there is no separation into valve leaflets [12] and separate commissures cannot be identified and sometimes referred as "Functional pulmonary atresia" in neonates. The pulmonary trunk is consistently dilated because of an inherent medial abnormality that is coupled with the morphology of the mobile dome-shaped valve, not with its functional state. Less commonly, the valve may be diffusely thickened, with one, two or three leaflets and commissural fusion.
Hypertrophy of the septal and parietal bands narrowing the right ventricular infundibulum often accompanies the pulmonic valve lesion, especially if it is severe and it is dynamic in nature. The adaptive response of the right ventricle to valvular pulmonic stenosis is characterized by an increase in thickness of the free wall and the ventricular septum [13] with normal cavity size [14] . In neonates with pinpoint pulmonic stenosis, cavity size is diminished. The elevation of right ventricular pressure is accompanied by an increase in muscle mass with a concomitant increase in number of capillaries [15] in the fetus and neonate and thus, the neonatal myocardium may be better adapted to generate the high pressure necessary to overcome the severe obstruction and the increased muscle mass may enable the hypertensive ventricle to maintain a normal stroke volume than in adults in whom no change in capillary network occurs.
If the size of the stenotic orifice remains fixed, however, the degree of obstruction becomes relatively more severe as the person grows. The right ventricle eventually may dilate and fail and this process is exacerbated by the development of tricuspid insufficiency in many patients with severe pulmonic stenosis. The patient may deteriorate rapidly, cardiac output becomes inadequate at rest, leads to right ventricular failure, which is the most common cause of death [16] .
Normal birth weight, growth and development are characteristic of mobile dome-shaped pulmonic valve stenosis and experience little or no difficulty in infancy and childhood [17] . Neonates with pinpoint pulmonic valve stenosis confront rapidly progressive condition further and early death.
Critical Pulmonic Stenosis
In utero, when the valvular pulmonic stenosis is severe, right ventricular output decreases and a large right-toleft shunt is established at atrial level and this condition has been termed as "critical pulmonic stenosis" [18] . Right ventricle is hypoplastic due to excessive hypertrophy and affected infants are cyanotic at birth with systemic or supra-systemic right ventricular pressures and the cyanosis persists for months after the stenosis is relieved until the hypertrophy decreases with an increase in right ventricular size.
It is surprising that an appreciable number of patients with moderate to severe pulmonic stenosis are asymptomatic. Patients with right ventricular systolic pressures between 50 and 100 mmHg include New Zealand longdistance runner and an English hockey captain [19] . A 17-year-old boy who played baseball despite a right ventricular systolic pressure of nearly 200 mmHg, and a woman who worked full-time with a right ventricular pressure of nearly 200 mmHg and died at the age of 60 years [20] . In Costello syndrome, the valvular pulmonic stenosis is usually non-progressive and found in 44% of cases and hypertrophic cardiomyopathy is chronic or progressive and found in 61% of cases and atrial septal defect was uncommon [21] . Calcific deposits are rare in congenital stenotic pulmonic valves and thickening of tricuspid valve may be present, and the valve may become regurgitant. The right atrium may be thick and dilated as a result of the increased pressure necessary to fill the hypertrophic right ventricle.
The most common cause of acquired valvular pulmonic stenosis is carcinoid heart disease. Interestingly, calcification of affected valve is rare and may be considered a notable negative echocardiographic feature of carcinoid heart disease [22] and lack of commissural fusion [23] .
The etiological differential features of valvular pulmonic stenosis are shown in Table 1 .
Clinical Characteristics
General Features
Individuals with Costello syndrome have characteristic craniofacial, musculoskeletal, cutaneous and cardiac abnormalities. Features include relative macrocephaly (abnormally large head), coarse facial feature such as epicanthal folds, full cheeks, low-set ears as shown in Figure 3 and wide nostrils. Musculoskeletal features include reduced range of mobility of shoulder and elbows, kyphoscoliosis as shown in Figure 3 , short stature as shown in Figure 2 and hip dysplasia. Skin may lack elasticity, wrinkled, thickened skin (plantar hyperkeratosis as shown in Figure 4 thickening of stratum corneum, the outermost layer of epidermis in sole, usually contains Symptoms may respond to somatostatinanaloges (octreotide, lanreotide).
Oral ketanserin for hypertensive crisis and intravenous octreotide to control hypotension. increased amount of the protective protein, keratin and associated with an increase in granular layer) and unusual tightening of the fibrous cords on the back of the heels (Achilles tendon) as shown in Figure 3 and Figure  4 . Cardiovascular manifestations include ventriculomegaly, valvular pulmonic stenosis, hypertrophic cardiomyopathy and atrial arrhythmias occasionally.
This child is having typical features of large head, skin folding below the lower eyelids as shown in Figure 1 , low set ears as shown in Figure 3 , teeth abnormalities as shown in Figure 1 and Figure 2 , short stature as shown in Figure 2 , ulnar deviation of forearm and cardiac manifestations of ventriculomegaly, valvular pulmonic stenosis, hypertrophic cardiomyopathy as in Figures 7-21 and warm sociable personalities as shown in Figure 1 , suggesting the Costello syndrome. Cardiac examination showed prominent systolic murmur over precordium, with ECG and X-ray features of Right ventricular hypertrophy as shown in Figure 5 and Figure 6 are consistent with severe valvular pulmonic stenosis. ECG based R wave height in V 1 × 5 to predict RV systolic pressure (17 × 5 = 70 mmHg) in this case is not correlated with echocardiographic RV (right ventricular) systolic pressure measurements (165 mmHg) and it may be due to chest wall deformity of kyphoscoliosis as shown in Figure 3 . Interestingly, TR (tricuspid regurgitation) jet velocity (6.30 m/s) correlates with PS (pulmonic valve stenosis) jet velocity of 6.30 m/s as shown in Figure 14 , Figure 15 and Figure 20. 
Echocardiographic Features
Transthoracic echocardiographic images revealed a thickened, calcified, bicuspid pulmonic valve with commissural fusion in 2D imaging as shown in Figures 10-12 . Color Doppler evaluation showed severe valvular pulmonic stenosis as in Figure 13 and Figure 14 and no pulmonary regurgitation as shown in Figure 17 . Continuous wave (CW) Doppler imaging revealed a high velocity valvular pulmonic stenosis jet (6.30 m/s) with a peak gradient of 160 mmHg as in Figure 14 and an overlap jet due to infundibular stenosis with a late systolic peaking (dagger-shaped) as in Figure 15 . Apical 4 chamber view revealed mild to moderate tricuspid regurgitation as in Figure 19 Figure 7 and Figure 8 and a dilated RV cavity as in Figure 9 rather than hypoplastic.
Treatment
Costello syndrome is a "RASopathy", characterized by increased growth at the prenatal stage, growth deficiency at postnatal stage with unique cardiovascular features of valvular pulmonic stenosis and hypertrophic cardiomyopathy. Animal models showed G12V mutation may also cause Costello syndrome and it does not appear to develop tumors as reported by Spanish researchers [24] , Italian and Japanese researchers [25] .
Specific Treatment
Treatment is directed towards the specific symptoms that are apparent in each individual. Bracing and physiotherapy may be used to treat skeletal abnormalities and surgery may be required to lengthen the tight tendoachilles. Cardiac abnormlities such as hypertrophic cardiomyopathy may be treated with beta-blockers or calcium channel blockers. Balloon valvuloplasty or surgical valve replacement may be utilized to relieve the stenotic obstruction of the pulmonary valve. MEK (mitogen-actvated ERK kinase) inhibitors such as cobimetinib, relumetinib and trametinib, Raf inhibitors such as sorafenib, encorafenib, dabrafenib and vemurafenib [26] also helps to inhibit the pathway closer to the cell nucleus in Costello syndrome.
Investigational Treatment
Congenital stenotic pulmonic valve rarely contains calcific deposits. Covambias and colleagues [27] reported calcific pulmonic stenosis in a 56-year-old man in whom the isolated stenotic lesion was treated by valve replacement with a bioprosthetic valve.
The valvular pulmonic stenosis is rarely progressive in Costello syndrome and the child was advised periodic follow-up. Since the stenotic pulmonic valve contains moderate calcification, this child may need valve replacement (bioprostheses) if any symptoms occur on follow up, rather than balloon valvuloplasty. The skeletal abnormalities were not affecting the normal activities and so bracing or physiotherapy was not advised. There are no obstructive manifestations such as syncopal episodes due to hypertrophic cardiomyopathy in this child, beta-blockers or calcium channel blockers were also not advised at this moment.
